Introduction
The continued evaluation of bacterial resistances to contemporary antimicrobial agents via modifications of targets requires the rapid search for agents with novel modes of action. Among the promising groups of candidate agents, the inhibitors of peptide deformylase (PDF) have emerged as potent agents with activity directed toward resistant Grampositive species. [1] [2] [3] The PDF was first described over 30 years ago and one inhibitor, actinonin, has been studied in some detail. 4 More recently, other novel PDF inhibitors have been synthesized that demonstrate activity (usually bacteriostatic) against staphylococci, Enterococcus faecalis, Bacillus spp. and some Escherichia coli. 2, 5 Owing to the unique enzyme target of these inhibitors, no evidence of cross-resistance has been noted, making the PDF inhibitors attractive alternatives for the therapy of emerging antimicrobial-resistant Grampositive infections. 3, 5 This report summarizes the antimicrobial potency and spectrum screening studies of NVP-PDF386 (VRC4887), a new PDF inhibitor. All tests were carried out by reference dilution methods 6 and the organism sample included resistant subsets derived from international surveillance studies. Table 1 compares the NVP-PDF386 (VRC4887) activity with that of selected agents against four key pathogens. NVP-PDF386 (VRC4887) showed excellent potency and spectrum against S. aureus (MIC 90 1 mg/L) that was equal to vancomycin (MIC 90 1 mg/L), was less active than the streptogramin (MIC 90 0.5 mg/L) and two-fold more potent than teicoplanin and linezolid (MIC 90 2 mg/L). The activity of NVP-PDF386 (VRC4887) against Enterococcus spp. was approximately two-fold less than that observed for S. aureus strains (49.0% MRSA), and two-fold more active against the S. pneumoniae strains (62% penicillin non-susceptible). All enterococcal and pneumococcal strains were inhibited by ≤4 and ≤1 mg/L of NVP-PDF386 (VRC4887), respectively. This PDF Table 2 summarizes the cumulative percentages of six additional bacterial groups inhibited by NVP-PDF386 (VRC4887). Coagulase-negative staphylococci showed a susceptibility like that described for NVP-PDF386 (VRC4887) against S. aureus. Similarly, the 150 strains of viridans group and β-haemolytic streptococci had results equal to that of S. pneumoniae versus NVP-PDF386 (VRC4887). M. catarrhalis was very susceptible to the PDF inhibitor (MIC 90 ≤0.25 mg/L); however, a mixture of 19 other species of Gram-positive organisms (Table 2 ; 26 strains) showed 88% of strains inhibited by ≤4 mg/L. The most PDF-resistant strains were the Nocardia spp. isolates. Anaerobes were moderately susceptible to the PDF inhibitor with all strains inhibited by ≤4 mg/L NVP-PDF386 (VRC4887). The Enterobacteriaceae and non-fermentative Gram-negative bacilli were resistant to NVP-PDF386 (VRC4887) ( Table 2 ) with an MIC 50/90 of >8 mg/L.
Materials and methods

Results
The isolates selected for use in this study were chosen to over-represent the key resistance mechanisms found in the individual bacterial species (resistance mechanisms in our sample are at a higher frequency than observed in contemporary clinical practice). Multidrug-resistant phenotypes among various species did not show increased MIC values of NVP-PDF386 (VRC4887). No differences in the MIC distribution of NVP-PDF386 (VRC4887) were observed between methicillin-susceptible (MSSA) and -resistant S. aureus (MRSA), methicillin-susceptible (MS-CoNS) and -resistant (MR-CoNS) CoNS, penicillin-susceptible and nonsusceptible streptococci, and macrolide-susceptible and -resistant Gram-positive strains.
Discussion
Several PDF inhibitors have been studied in vitro, each having primary activity against Gram-positive organisms and some Gram-negative coccobacilli such as M. catarrhalis and H. influenzae. 3, 8 Although PDF inhibitory activity has generally been classified as bacteriostatic, some reports have demonstrated bactericidal action against staphylococci, some Table 1) . The activity of NVP-PDF386 (VRC4887) was lower for isolates of H. influenzae (MIC 50/90 8/32 mg/L); however, pending bioavailability studies may indicate an expanded use of the PDF inhibitor for community-acquired respiratory tract infections, not limited to a role in therapy for resistant Grampositive pathogens. 2, 3 Mutational rates to resistance for PDF inhibitors have been reported over the range of 10 -7 to 10 -9 for both Gram-positive and -negative species. 1, 5 Again these rates were comparable to those obtained with other antimicrobial classes studied. Animal septicaemia models have proven the PDF inhibitors to be viable candidates for therapy of staphylococcal and enterococcal infections. 2, 8 The clinical isolates utilized in our study were selected to significantly test key resistance mechanisms within individual bacterial species, and the in vitro results indicate that further studies of NVP-PDF386 (VRC4887) use in the treatment of infections caused by multi-resistant Gram-positive cocci are warranted. Further modification of PDF structures could expand the spectrum of activity to include key Gramnegative pathogens. 
